---
figid: PMC6874786__Cell-J-22-193-g01
figtitle: PI3K/AKT/mTOR pathway in AML
organisms:
- Homo sapiens
- Erythrina poeppigiana
pmcid: PMC6874786
filename: Cell-J-22-193-g01.jpg
figlink: pmc/articles/PMC6874786/figure/F1/
number: F1
caption: Overview of the PI3K/AKT/mTOR pathway in AML. The PI3K/AKT/mTOR pathway and
  other pathways related to AML, Inducing autophagy by inhibiting the mTOR pathway.
  Diagram shows that ATO promotes apoptotic mechanisms. Left, PI3K/Akt/NF-κB pathway
  permanently activated in the absence of ATO. Right, ATO by inducing JNK activation,
  can inhibit the PI3K/Akt/NF-κB signalling pathway. THAL has anti-angiogenesis effects
  on tumour growth and progression. THAL inhibits IL6. ATO/THAL by inhibition of mTORC1
  induces dephosphorylation of ULK1 and subsequent ULK1-mediated phosphorylation of
  ATG13, FIP200 and ULK1 itself, inducing autophagosome synthesis. Release of BCL-2
  suppresses BECLIN1 that induces autophagy through disruption of the BCL-2/BCL- XL-BECLIN1
  interaction. In case of existence of sufficient nutrients, BECLIN1 binds to BCL-2
  or BCL-XL, and loses its ability to initiate autophagy. AML; Acute myeloid leukemia,
  ATO; Arsenic trioxide, and THAL; Thalidomide.
papertitle: Arsenic Trioxide and Thalidomide Combination Induces Autophagy Along with
  Apoptosis in Acute Myeloid Cell Lines.
reftext: Mahnaz Mohammadi Kian, et al. Cell J. 2020 Summer;22(2):193-202.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9588603
figid_alias: PMC6874786__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC6874786__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6874786__Cell-J-22-193-g01.html
  '@type': Dataset
  description: Overview of the PI3K/AKT/mTOR pathway in AML. The PI3K/AKT/mTOR pathway
    and other pathways related to AML, Inducing autophagy by inhibiting the mTOR pathway.
    Diagram shows that ATO promotes apoptotic mechanisms. Left, PI3K/Akt/NF-κB pathway
    permanently activated in the absence of ATO. Right, ATO by inducing JNK activation,
    can inhibit the PI3K/Akt/NF-κB signalling pathway. THAL has anti-angiogenesis
    effects on tumour growth and progression. THAL inhibits IL6. ATO/THAL by inhibition
    of mTORC1 induces dephosphorylation of ULK1 and subsequent ULK1-mediated phosphorylation
    of ATG13, FIP200 and ULK1 itself, inducing autophagosome synthesis. Release of
    BCL-2 suppresses BECLIN1 that induces autophagy through disruption of the BCL-2/BCL-
    XL-BECLIN1 interaction. In case of existence of sufficient nutrients, BECLIN1
    binds to BCL-2 or BCL-XL, and loses its ability to initiate autophagy. AML; Acute
    myeloid leukemia, ATO; Arsenic trioxide, and THAL; Thalidomide.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - KRAS
  - HRAS
  - NRAS
  - MAPK8
  - MAPK9
  - MAPK10
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PTEN
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - GTF2H1
  - SQSTM1
  - KHDRBS1
  - NUP62
  - DCTN4
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - NFKB1
  - MTOR
  - RPTOR
  - EPHB2
  - MAPK1
  - MAPK3
  - IL6
  - SGSM3
  - STAT3
  - MYC
  - CRK
  - MAPK14
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - POU5F1
  - POU5F1P3
  - POU5F1P4
  - ATG5
  - ATG7
  - BCL2
  - BECN1
  - BAX
  - ATG12
  - ATO
---
